Lupin Limited has announced the allotment of 135,892 equity shares under its Employee Stock Option Plan (ESOP), marking another milestone in its employee incentive program. The pharmaceutical company's Operations and Finance Committee approved this allotment during its meeting held on March 24, 2026.

Share Allotment Details

The allotment comprises 135,892 fully paid-up equity shares with a face value of ₹2/- each. These shares were issued following the exercise of vested options by employees of Lupin Limited and its subsidiaries under the company's existing stock option plans.

Updated Share Capital Structure

Following this ESOP allotment, Lupin's capital structure has been revised upward. The company's issued and paid-up share capital has increased to ₹91,43,58,222, consisting of 45,71,79,111 equity shares of ₹2/- each.

Regulatory Compliance

The allotment was disclosed to stock exchanges in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both the National Stock Exchange of India Limited and BSE Limited about this development.

The disclosure was signed by Amit Kumar Gupta, Company Secretary and Compliance Officer, ensuring proper regulatory adherence and transparency in the share allotment process.

Lupin Manufacturing Solutions (LMS), a global Contract Research, Development and Manufacturing Organization (CRDMO) and subsidiary of Lupin Limited, has announced a strategic expansion of its Dabhasa manufacturing facility in India. This expansion represents a significant step toward strengthening the company's development and manufacturing capabilities, particularly in peptide manufacturing and complex therapeutics.

Facility Expansion Overview

The expansion of the Dabhasa facility introduces several key enhancements designed to boost manufacturing capabilities:

These upgrades are specifically designed to support the growing global demand for advanced pharmaceutical solutions, with particular emphasis on complex modalities such as peptides and biologic ADCs.

Strategic Impact on Development Capabilities

Dr. Abdelaziz Toumi, Chief Executive Officer of Lupin Manufacturing Solutions, emphasized the strategic importance of this expansion: "As pharmaceutical innovation increasingly shifts toward complex modalities, building deep capabilities and execution excellence has become critical. This expansion underscores our commitment to building advanced, scalable capabilities that support complex development programs and reinforce our role in the global peptide ecosystem, enabling meaningful partnerships with innovators worldwide."

The facility expansion directly addresses the evolving landscape of drug development, which is increasingly characterized by molecular complexity. The enhanced capabilities will enable LMS to consistently supply high-quality peptide building blocks, including protected amino acids, positioning the company as a key player in supporting complex therapeutic development.

About Lupin Manufacturing Solutions

Lupin Manufacturing Solutions Limited operates as a wholly owned subsidiary of Lupin Limited, functioning as a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and a global CDMO. The organization offers comprehensive solutions spanning:

• Drug substances and complex chemistry
• Drug product development
• Advanced modalities including ADCs and peptides
• Integrated solutions from early development to commercial scale

LMS leverages Lupin's established legacy of scientific rigor and regulatory expertise to support biopharma innovators. The company operates with state-of-the-art facilities, maintains a client-first approach, and employs a team of over 250 scientists dedicated to accelerating the path to market for transformative therapies.

Company Profile

Lupin Limited serves as a global pharmaceutical leader headquartered in Mumbai, India, with products distributed across over 100 markets worldwide. The company maintains a strong position in India and the U.S. across multiple therapy areas:

The expansion announcement demonstrates Lupin's continued commitment to strengthening its manufacturing infrastructure and enhancing its capabilities in complex pharmaceutical development and production.